Biopharmaceutics Oral Flashcards

1
Q

Describe the simple model of dissolution

A
  • drug molecules diffuse from the saturated diffusion layer into different compartments (e.g. the blood)
  • this sets up a concentration gradient
  • as the drug molecules move into the bulk fluid from the diffusion layer, more molecules are drawn into the diffusion layer meaning that it will remain saturated (sink conditions)
  • the rate of dissolution is the rate limiting step
  • sink conditions = first order kinetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What needs to be considered with the diffusion layer?

A
  • pH of the diffusion layer around each drug particle may be different

by NOT considering this you may over-estimate the rate of ionisation and therefore dissolution of weak acids in the intestine and weak bases in the stomach

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Why are the dissolution rates of weak acids in the stomach low?

A
  • environment has an abundance of protons
  • all of the weak acid molecules will be protonated, and therefore unionised
  • diffusion layer will not possess a charge
  • drug is therefore poorly soluble
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What would improve the dissolution rates of weak acids in the stomach?

A
  • making an ALKALINE salt of the weak acid (as it dissolves it would release hydroxide ions, which are basic, making a more alkaline environment in the diffusion layer)
  • Na and K salts dissolve more rapidly than free acids, regardless of the local pH and will release hydroxide ions, which will promote drug ionisation and therefore dissolution
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How do small hydrophilic compounds permeate the gut wall?

A

PARAcellular water channels, between cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do lipophilic compounds permeate the gut wall?

A

TRANScellular route, partition into the lipid bilayer of cell membranes, through cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is Log P?

A

a measure of lipophilicty, the partition coefficient of only the UNIONISED drug between aqueous and lipophilic phases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is pKa?

A

describes the extent to which a drug is ionised

  • when the pH is the same as the pKa, 50% of the drug will be ionised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is D/Log D?

A

the distribution coefficient (the partition coefficient) expect that it accounts for the degree of ionisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the D calculation for weak acids?

A

unionised organic/(unionised aqueous + ionised aqueous)

[HAorganic] / { [HAaqueous] + [A-aqueous] }

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the D calculation for weak bases?

A

unionised organic/(unionised aqueous + ionised aqueous)

[Borganic] / { [Baqueous] + [BH+aqueous] }

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the Log D calculation?

A

Log D = Log P - Log (1 + Antilog (pKa - pH))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Log D is pH dependent, true or false?

A

True
- because it takes into account the ionised and the unionised form, so is dependent on pH as this would affect the ionisation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is the Log D calculation limited?

A

it doesn’t take into account

  • unstirred conditions
  • connective flow
  • absorption of ionised species
  • different pH at the membrane surface
  • disruption of the lipid membrane

the calculation gives a good APPROXIMATION of Log D

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the absorption rate of carrier-mediated transport?

A

absorption rate = Vmax C/ (Km + C)

  • C is the free drug concentration at the site of absorption (not complexed to the carrier)
  • Km is a constant relating to the affinity of the carrier that binds the drug
  • Vmax is a constant relating to the maximum rate of transport (saturation of the carriers)

this assumes that the absorption rate = the rate of the carrier mediated transport

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the generalisations of a weakly basic drug in the stomach?

A
  • the weakly basic drug will be IONISED, and will therefore have high dissolution in the stomach
  • this means that the permeability of the drug will be lower as the drug is now less lipophilic
    (however the drug is not designed for permeation with a low SA)
  • the presence of food ENHANCES the dissolution and therefore the solubility:
    1. slows the gastric emptying time, so that the drug stays in the stomach for longer, giving it more time to dissolve
    2. presence of food stimulates the stomach to produce more acid, reducing the pH and increasing the ionisation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the generalisations of a weakly basic drug in the intestine?

A
  • the weakly basic drug will be UNIONISED, and will therefore have low solubility in the intestine
  • this means that the drug will be more lipophilic as it is uncharged, and has a higher permeability
  • the intestine has a high SA and a good blood flow, which will set up sink conditions and therefore a concentration gradient for the drug to be absorbed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What varies blood flow?

A
  • varies from person to person
  • after a meal there is a higher blood flow
  • if ill/resting/in shock there is a lower blood flow
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What are the generalisations of a weakly acidic drug in the stomach?

A
  • the weakly acidic drug will be UNIONISED, as there is a high concentration of protons in the stomach
  • this means that the drug has low solubility but high permeability (however the stomach is not designed for permeation as it has a low SA)
  • presence of food will NOT enhance solubility, and will only increase the retention time
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are the generalisations of a weakly acidic drug in the intestine?

A
  • the weakly acidic drug will be IONISED, as there is an increase in the pH
  • this means that the drug is less permeable, but increased solubility
  • although less permeable, there will still be enough of the unionised form being absorbed in order to set up a concentration gradient
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the pKa of a strong acid and strong base, and are they influenced by changes in the pH?

A

strong acid: < 2
strong base: > 11

they are UNLIKELY to be affected by changes in the pH as they will be ionised at most pH values

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the pKa of a very weak acid and a very weak base, and are they influenced by changes in the pH?

A

very weak acid: > 8
very weak base: < 7

they are UNLIKELY to be affected by changes in the pH as they will be unionised at most pH values

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the pKa of moderately weak acids and bases, and are they influenced by changes in the pH?

A

moderately weak acid: 2.5 - 7.5
moderately weak base: 7 - 10

these will be affected by changes in the pH

24
Q

What is the effect of pH on ionisation, or pKa on moderately weak acids?

A

pH value of 2 ABOVE the pKa of an acid will mean that there will be 99% IONISED

pH value of 2 BELOW the pKa of an acid will mean that there will be 99% UNIONISED

25
Q

What is the effect of pH on ionisation, or pKa on moderately weak bases?

A

pH value of 2 ABOVE the pKa of a base will mean that there will be 99% UNIONISED

pH value of 2 BELOW the pKa of a base will mean that there will.be 99% IONISED

26
Q

What is the volume of fluid in the stomach when it is empty?

A

100mL

27
Q

What is the BCS classifications?

A
  1. High Solubility and High Permeability
  2. Low Solubility and High Permeability
  3. High Solubility and Low Permeability
  4. Low Solubility and Low Permeability
28
Q

What is a biowaiver?

A

where you don’t need to submit bioavailability data to get product approval

29
Q

What BCS classifications are eligible for a biowaiver?

A
  • Class 1 - fewer of these compounds are being identfied
  • Class 2 IF they are weak acids, and highly soluble at pH 6.8
  • Class 3 IF they are rapidly dissolving
30
Q

When is a drug considered to be highly soluble?

A

when the HIGHEST dose required dissolves in < 250mL of water over a pH range of 1 - 7.5

31
Q

When is a drug considered to be highly permeable?

A

when over 90% of the administered dose is absorbed

32
Q

What solubility values is problematic in drug development?

A
  • < 10mg/mL will impair the solubilisation when formulating

- < 0.1mg/mL will cause significant problems

33
Q

What are the in vivo consequences of a poorly soluble drug?

A
  • decreased bioavailability
  • suboptimal dosing
  • increased chance of food affecting solubility
  • increased issues in patients with diseases (variable blood flow for example, in GI issues)
  • more incomplete releasing of the drug from the dosage form
  • lack of dose proportionality (doubling the dose won’t mean double the concentration)
  • higher variability in different patients for bioavailability
  • patient compliance due to the inconvenience of a different formulation/regimen
34
Q

What are the formulation consequences of a poorly soluble drug?

A
  • severely limited choice of delivery technologies
  • complex dissolution testing
  • limited/poor reflection of in vivo absorption (harder to predict), this can be severe enough to halt product development
  • harsh excipients required
  • use of extreme basic/acidic conditions
  • uncontrollable precipitation
35
Q

What are the factors that affects solubility and permeability?

A
  • wettability
  • surfactants
  • particle size
  • solid dispersions
  • polymorphs
  • pH solubility
  • soluble prodrugs
  • complexation
  • adsorbents
  • viscosity enhancing agents
  • degradation
  • diluents
36
Q

How would you improve the solubility of Class 2 compounds?

A
  • particle size reduction
  • soluble salts
  • solid dispersion
  • self-emulsifying systems
  • surfactants
  • nanoparticles
  • cyclodextrin
  • pH of diffusion layer
37
Q

How would you improve the permeability of Class 3 compounds?

A
  • permeation enhancer
  • absorption enhancing excipients
  • efflux inhibitors
  • lipid-filled capsules
  • GI motility consideration
38
Q

How would you improve a Class 4 compound?

A
  • prodrugs
  • salt forms
  • co-solvents
  • solubilisation by surfactants
  • lipid-filled capsules
  • nanoparticles
  • liposomes
  • lyophilisation
39
Q

What is a cyclodextrin?

A

has a hydrophobic interior and hydrophilic exterior so can form complexes with HYDROPHOBIC compounds

40
Q

How is a cyclodextrin formed?

A
  • supersaturating a cyclodextrin solution with a drug (with agitation)
  • kneading a drug/CD/solvent slurry into a paste, and then dry and sieve
41
Q

How do you enhance the effects of a cyclodextrin?

A
  • include a hydrophilic polymer (HPMC) to improve the solubilising effects of the CD (so that less of the CD is needed to soluble the same amount of drug)

so the poorly soluble compound will sit in the hydrophobic pocket and when they reach the intestine will spontaneously dissociate and release the poorly soluble drug (only bonded by covalent bonds, which aren’t that strong)

few oral CD drug products are available on the market because of toxicity and stability issues

42
Q

What is an amorphous solid compound?

A

an amorphous solid lacks a crystalline structure, so is more soluble (but also more prone to recrystallisation because they are more unstable)

43
Q

How is an amorphous solid dispersion formed?

A

formulation with polymers:

  • spray dry using solvents or replace with supercritical fluids
  • hot melt extrusion - soften the polymer, add drug and mix to get a homogenous mix, then rapidly cool and mill the strands to a finer powder to increase SA
44
Q

What polar excipients can be added to improve solubility?

A
  • polyethylene glycol
  • gelatine
  • sugar glasses (inulin)
  • lipids
45
Q

How does polyethylene glycol enhance solubility?

A

Solid Dosage Forms:

  • wetting agent or enhances dispersion of solid dosage forms
  • encorporated by solvent evaporation or freeze drying

Liquid Based Dosage Forms:
- co-solvent to prevent the precipitation of compounds that are poorly soluble

  • suitable for topical and parenteral administration
  • can be used with other excipients (stearic acid, sodium lauryl sulphate)
46
Q

How does gelatine enhance solubility?

A
  • naturally derived collagen extract
  • positive and negative charges
  • binds to the poorly soluble compound and increases solubility

can be used to improve gettability of hydrophobic compounds when used as a granulating agent

47
Q

How does sugar glasses (inulin) enhance solubility?

A
  • naturally occurring fructose polymer
  • mix with drug solution, then freeze dry to create a sugar glass
  • sugar glasses improve dissolution and protects the drug from physical and chemical degradation, increasing stability
48
Q

How do lipids enhance solubility?

A

lipids are used as polar excipients in self emulsifying systems

49
Q

How does particle engineering enhance solubility?

A

reducing the particle size will increase the surface area and enhance dissolution

  • recrystallisation of poorly soluble materials using liquid solvents and anti-solvents requires organic solvents (increasing complexity of manufacture)
  • conventional methods of communition and spray-drying relies on mechanical stress (not good for thermosensitive/unstable compounds)
50
Q

What are the benefits of nanoparticle formulations?

A
  • bioavailability is improved (C Max and AUC)
  • less variability with food
  • dose proportionality (the AUC is proportional to the dose, double the dose = double the AUC)
51
Q

How does nanoparticle formulations enhance dissolution?

A
  • the nanoparticles do not get absorbed directly, these dissolve
  • increasing the surface area to increase the rate of dissolution as there is more contact with the solution
52
Q

How are nanoparticles formed?

A
  • traditional methods (grinding, milling) won’t create particle sizes small enough
  • micro-milling may operate down to sub-micron sizes but has physical/thermal stresses
  • piston gap methods, through hydrodynamic cavitation

OR

  • supercritical fluids, by the control of solubility using pressure and temperature in solvents such as carbon dioxide
53
Q

How do supercritical fluids work?

A
  • above the SCF’s critical point, they assume the properties of both a liquid and a gas
    (they can diffuse through solids like a gas and dissolve materials like a liquid)
  • drug particles soluble in the SCF can be re-crystallised to smaller particles sizes 5 - 2000nm in diameter
  • at critical temperatures, SCFs are highly compressible, and small changes in temperature and pressure can change their density, mass transport and solvating power
54
Q

How is a self-emulsifying lipid formulation made?

A
  • incorporate the drug into an oil-surfactant mixture, and load into a hard/soft gelatine capsule
  • can include non-ionic surfactants to improve solubility and prevent drugs precipitating out
55
Q

What are the different lipid formulation classifications?

A
  • SEDDS - self-emulsifying drug delivery system
  • SMEDDS - self-microemulsifying drug delivery system
  • SNEDDS - self-nanoemulsifying drug delivery system

larger particles are less likely to be affected by dissolution and may need digestion by bile acids for drug release

56
Q

How do the self-emulsifying systems enhance solubility?

A
  • lipids present in the duodenum stimulates the release of biliary lipids
  • this forms colloidal micelles/mixed micelles/emulsion droplets
  • digestion of the lipids is an IMPORTANT STEP for the bioavailability enhancement
  • drugs are absorbed into the intestinal lymphatics, and into systemic circulation, avoiding first pass metabolism
  • the droplets/emulsions enter the enterocytes and are packaged into chylomicrons

EXPLOIT the normal lipid absorption by using lipid-based formulations